top of page
PharmaTell Banner Med Finance.jpeg

Eyes On Pharma Blog 

EyesOn Competitive Strategy

  • Writer: Jana Chisholm
    Jana Chisholm
  • 7 days ago
  • 3 min read

Strategic Reallocation in Action: Takeda, Daiichi Sankyo, and Shionogi refocus for Growth and Market Access. Portfolio exits, capital shifts, and U.S. manufacturing expansion highlight how companies are actively adjusting strategic levers.



Executive Highlights

  • Takeda is restructuring operations, including 634 U.S. layoffs and reduced investment in non-core R&D areas.

  • Daiichi Sankyo is divesting its consumer health unit (~$1.55B) to focus on oncology and ADC leadership.

  • Shionogi is expanding U.S. manufacturing through a BARDA-backed deal worth up to $482M.

  • Portfolio and capital reallocation is accelerating as companies shift investment toward core therapeutic areas and priority markets.


What Happened: Portfolio and Strategy Reset

Several recent announcements highlight how pharma companies are actively reshaping their strategies.

  • Takeda has exited partnerships and reduced R&D focus

  • Daiichi Sankyo is divesting non-core consumer health assets

  • Shionogi is investing in U.S.-based manufacturing


While different on the surface, these actions reflect a shared theme:

companies are actively adjusting multiple strategic levers to align with long-term priorities and evolving market conditions.


Key Data Points

Takeda

  • Restructuring program: $1.3B

  • Workforce reduction: 634 U.S. employees 

  • Exit from select R&D areas including mRNA collaboration

  • Reduced investment in cell therapy and U.S. footprint


Daiichi Sankyo

  • Consumer health divestiture: $1.55B

  • Strategic focus: oncology and ADCs

  • Target: 700,000 eligible patients by 2030 (vs ~120,000 today)


Shionogi

  • BARDA contract: $119M upfront → up to $482M total 

  • U.S. manufacturing expansion for Fetroja

  • Additional development in biothreat-related indications


Capital Allocation as Strategy

Across these companies, a clear pattern is emerging:

Capital Allocation is becoming the primary strategic lever.

  • Takeda → reducing spend in lower-priority R&D areas

  • Daiichi → redeploying capital from consumer health to oncology

  • Shionogi → investing in manufacturing tied to government demand


This reflects a broader shift from:

  • Portfolio breadth → to focused investment in high-return segments 


Strategic Meaning: Multi-Lever Strategy in Practice

These moves reinforce a broader trend: companies are managing multiple strategic levers simultaneously.


These include:

  • Portfolio focus

  • R&D investment

  • Geographic footprint

  • Manufacturing and supply chain

  • Market access strategy


Rather than optimizing a single dimension, success increasingly depends on how effectively these levers are aligned.


Case Study: Takeda — Resetting the Portfolio

Takeda is prioritizing efficiency and focus.

Key actions:

  • Exiting non-core R&D programs

  • Reducing exposure to capital-intensive modalities

  • Streamlining workforce and infrastructure


👉 This represents reallocation toward higher-confidence growth areas, not simply cost-cutting.


Case Study: Daiichi Sankyo — Doubling Down on Core Strength

Daiichi Sankyo is sharpening its focus on oncology.

Key drivers:

  • Success of ADCs (Enhertu, Datroway)

  • Clear expansion opportunity across tumor types


By divesting consumer health, Daiichi is:

  • Freeing capital

  • Simplifying operations

  • Reinforcing its strategic identity


Case Study: Shionogi — Manufacturing as Market Access Strategy

Shionogi is expanding U.S. manufacturing through a BARDA-supported initiative.

This reflects growing alignment between:

  • Manufacturing location

  • Government procurement

  • Pricing and access strategy


Key drivers include:

  • BARDA and BioShield funding programs

  • “Buy American” preferences

  • Potential MFN-related pricing considerations

  • Supply chain resilience priorities


👉 Manufacturing is increasingly a strategic lever for securing market access, not just an operational decision.


Broader Industry Context

These actions mirror wider industry trends:

  • Consumer health divestitures (Sanofi, GSK, J&J)

  • Increased focus on specialty and oncology portfolios

  • Geographic realignment toward the U.S. and other high-value markets


What to Watch

  • Continued portfolio divestitures across large pharma

  • Expansion of U.S.-based manufacturing tied to policy incentives

  • Narrowing of R&D focus across therapeutic areas

  • Increasing alignment between supply chain and market access strategy


🔑 Key Takeaway

Strategic advantage is increasingly defined by how effectively companies allocate capital, align portfolios, and position operations against evolving market and policy dynamics.


Further Reading from PharmaTell Studio

 

bottom of page